Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.37 |
| ▸ | METAP1 | P53582 | 4/20 | 0.37 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181801 | 0.81 | BTN3A1 (0.37) | METAP2METAP1BTN3A1GAAMGAM | |
| SCHEMBL21704580 | 0.78 | METAP2 (0.30) | METAP2METAP1 | |
| SCHEMBL19803893 | 0.77 | BTN3A1 (0.55) | BTN3A1POLB | |
| SCHEMBL18583754 | 0.77 | BTN3A1 (0.55) | BTN3A1POLB | |
| SCHEMBL18583546 | 0.77 | BTN3A1 (0.55) | BTN3A1POLB | |
| SCHEMBL18061730 | 0.77 | BTN3A1 (0.55) | BTN3A1POLB | |
| SCHEMBL22356079 | 0.76 | METAP2 (0.37) | METAP2METAP1BTN3A1GAACYP3A4 | |
| SCHEMBL21704812 | 0.76 | BTN3A1 (0.36) | METAP2METAP1BTN3A1GAAMGAM | |
| SCHEMBL20181855 | 0.76 | TDP1 (0.39) | METAP2METAP1BTN3A1GAACYP3A4 | |
| SCHEMBL22413839 | 0.75 | CNR1 (0.33) | GAACYP3A4CYP2C9CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CDK2, CDK3 | METAP2 3309/4885METAP1 2390/4885BTN3A1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.